宫颈鳞癌新辅助化疗敏感性预测指标的研究  

A Study of Indicator of Sensitivity to Neoadjuvant Chemotherapy in Cervical Squamous Carcinoma

作　　者：王莉[1] 刘风花[1] 刘若男[1] 

机构地区：[1]河南省肿瘤医院,河南郑州450008

出　　处：《中国肿瘤》2005年第9期622-624,共3页China Cancer

摘　　要：[目的]观察CD44v6、PCNA、Ki鄄67作为宫颈鳞癌新辅助化疗治疗敏感性预测指标的可行性。[方法]24例宫颈鳞癌患者采用顺铂、羟基喜树碱、博来霉素方案进行术前2个疗程的新辅助化疗,对化疗前的宫颈鳞癌组织以流式细胞术检测组织中CD44v6及PCNA、Ki鄄67的表达,研究三者与化疗疗效之间的关系。[结果]化疗前宫颈鳞癌组织中CD44v6及PCNA、Ki鄄67平均检测值分别为0.481±0.150、0.386±0.078、0.550±0.127;临床观察化疗有效率为83.3%,化疗后肿瘤病灶缩小程度平均为0.633±0.214。化疗后肿瘤病灶缩小与CD44v6之间呈显著负相关(r=-0.853,P<0.001),与PCNA、Ki鄄67检测值无显著相关性(r=0.057,P=0.791;r=0.022,P=0.919)。[结论]CD44v6可以作为宫颈鳞癌新辅助化疗治疗敏感性预测指标。[Purpose] To investigate the feasibility of CD44v6, proliferating cell nuclear antigen （PCNA） and Ki-67 as a sensitive and predicative indicators for the response to neoadjuvant chemotherapy （NAC） in eervieal squarnous carcinoma. [Methods] Twenty-four patients with cervix squamous carcinoma were treated with two cycles NAC with cisplatin , hydroxycarnptothecine and bleornycin regimen before operation. The expression of CD44v6, PCNA and Ki-67 in tumor tissues before NAC was detected with flow cytornetry. The relationships of expression of three markers and therapeutie efficacy of NAC were analyzed. [Results] The average level of CD44v6, PCNA and Ki-67 in tumor tissues before NAC was 0.481±0.150, 0.386±0.078, 0.550±0.127 respectively. The response rate of NAC was 83.3%, the average tumor volume reduced to 0.633±0.214. The reduction of tumor volume after NAC was significantly negative correlated to expression of CD44v6 （r=-0.853, P〈0.001）; but there was no significant correlation with the expression of PCNA and Ki-67 （r=0.057,P=0.791; r=0.022,P=0.919）. [Conclusion ] CD44v6 could be used as a sensitive and predicative indicator for neoadjuvant chemotherapy in cervical squamous carcinoma.

关 键 词：宫颈肿瘤 新辅助化疗 增殖细胞核抗原 KI-67 CD44V6 

分 类 号：R737.33[医药卫生—肿瘤]